Skip to main content

Table 2 Best response per RECIST v1.1

From: A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer

Category

N

Denominator

Proportion (%)

Lcl (%)

Ucl (%)

PD

16

18

88.9

65.29

98.62

SD

1

18

5.6

0.14

27.29

PR

1

18

5.6

0.14

27.29

CR

0

18

0.0

0.00

18.53

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us